Moderna announced that the first participant in the Phase II clinical trial of the candidate for a bivalent booster dose for the Omikron variant (mRNA-1273.214) has been vaccinated. This preparation is a combination of a candidate Omikron ...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
